TERNS PHARMACEUT.DL-0001
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hor… Read more
TERNS PHARMACEUT.DL-0001 (430) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, TERNS PHARMACEUT.DL-0001 (430) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
TERNS PHARMACEUT.DL-0001 - Net Assets Trend (None–None)
This chart illustrates how TERNS PHARMACEUT.DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TERNS PHARMACEUT.DL-0001 (None–None)
The table below shows the annual net assets of TERNS PHARMACEUT.DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to TERNS PHARMACEUT.DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
TERNS PHARMACEUT.DL-0001 Competitors by Market Cap
The table below lists competitors of TERNS PHARMACEUT.DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Axonics Inc
F:0I3
|
$3.29 Billion |
|
Baic Bluepark New Energy Technology
SHG:600733
|
$3.29 Billion |
|
Kintetsu Group Holdings Co.Ltd
F:KKI
|
$3.29 Billion |
|
GlobalWafers Co Ltd
TWO:6488
|
$3.29 Billion |
|
Gerdau S.A
SA:GGBR3
|
$3.29 Billion |
|
KANDENKO CO. LTD
F:5EY
|
$3.29 Billion |
|
Industrias Penoles Sab De CV
PINK:IPOAF
|
$3.28 Billion |
|
Renasant Corporation
NYSE:RNST
|
$3.28 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TERNS PHARMACEUT.DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares TERNS PHARMACEUT.DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently TERNS PHARMACEUT.DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares TERNS PHARMACEUT.DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TERNS PHARMACEUT.DL-0001 (430) | €- | N/A | N/A | $3.29 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |